# EDGAR Filing Document

**Accession Number:** 0001954594
**File Stem:** 0001213900-26-014275
**Filing Date:** 2026-2
**Character Count:** 3638
**Document Hash:** 21b2ff548130aff201438febd8515a93
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-014275.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001213900-26-014275

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260210

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Haoxi Health Technology Ltd
- **CENTRAL INDEX KEY:** 0001954594
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-ADVERTISING AGENCIES [7311]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41933
- **FILM NUMBER:** 26616147

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 801/802, TOWER C, BUILDING 103
- **STREET 2:** HUIZHONGLI, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **NON US STATE TERRITORY:** CHINA
- **PROVINCE COUNTRY:** F4
- **ZIP:** 100101
- **BUSINESS PHONE:** 86-10-13311587976

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 801/802, TOWER C, BUILDING 103
- **STREET 2:** HUIZHONGLI, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **NON US STATE TERRITORY:** CHINA
- **PROVINCE COUNTRY:** F4
- **ZIP:** 100101

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

**Commission File Number: 001-41933**

**HAOXI HEALTH TECHNOLOGY LIMITED.**

**Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District**

**Beijing, China**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Termination of a Material Definitive Agreement**

As previously disclosed, on January 23, 2026, Haoxi Health Technology Limited, a Cayman Islands exempted company (the "Company"), entered into a sales agreement (the "Sales Agreement") with Aegis Capital Corp (the "Sales Agent"), establishing an at-the-market equity program. According to the Sales Agreement, the Company may offer and sell, from time to time, through or to the Sales Agent, up to $80 million of the Company's Class A ordinary shares, par value $0.0025 each (the "Class A Ordinary Shares"), pursuant to the Company's registration statement on [Form F-3](http://www.sec.gov/Archives/edgar/data/1954594/000121390025049485/ea0243195-f3_haoxi.htm), as amended, (File No. 333-287686), initially filed with the U.S. Securities and Exchange Commission on May 30, 2025, and declared effective on June 13, 2025, and the prospectus supplement, dated January 23, 2026.

On February 7, 2026, the Company and the Sales Agent entered into a certain mutual termination agreement, pursuant to which, the Sales Agreement and all related agreements contemplated thereunder were terminated and had no further force and effect, effective on February 7, 2026. The Company did not sell any Class A Ordinary Shares pursuant to the Sales Agreement.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Haoxi Health Technology Limited** | **Haoxi Health Technology Limited** |
| Date: February 10, 2026 | By: | */s/ Zhen Fan* |
|  | Name: | Zhen Fan |
|  | Title: | Chief Executive Officer |

---